These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 31640596)

  • 81. Simplification of antiviral hepatitis C virus therapy to support expanded access in resource-limited settings.
    Ford N; Swan T; Beyer P; Hirnschall G; Easterbrook P; Wiktor S
    J Hepatol; 2014 Nov; 61(1 Suppl):S132-8. PubMed ID: 25443341
    [TBL] [Abstract][Full Text] [Related]  

  • 82. New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents.
    Quer J; Buti M; Cubero M; Guardia J; Esteban R; Esteban JI
    Infect Drug Resist; 2010; 3():133-45. PubMed ID: 21694902
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection.
    Frigeni M; Besson C; Visco C; Fontaine H; Goldaniga M; Visentini M; Pulsoni A; Torres HA; Peveling-Oberhag J; Rossotti R; Zaja F; Rigacci L; Merli M; Dorival C; Alric C; Piazza F; Gentile M; Ferrari A; Pirisi M; Nassi L; Rattotti S; Frustaci A; Milella M; Cencini E; Defrancesco I; Ferretti VV; Bruno R; Hermine O; Arcaini L
    Leukemia; 2020 May; 34(5):1462-1466. PubMed ID: 31836855
    [No Abstract]   [Full Text] [Related]  

  • 84. Real World Cost-of-Illness Evidence in Hepatitis C Virus: A systematic review.
    Mattingly TJ; Love BL; Khokhar B
    Pharmacoeconomics; 2020 Sep; 38(9):927-939. PubMed ID: 32533524
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Hepatitis C virus genotype 3: clinical features, current and emerging viral inhibitors, future challenges.
    Shahnazarian V; Ramai D; Reddy M; Mohanty S
    Ann Gastroenterol; 2018; 31(5):541-551. PubMed ID: 30174390
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Opportunities and Risks of Host-targeting Antiviral Strategies for Hepatitis C.
    Gerold G; Pietschmann T
    Curr Hepat Rep; 2013; 12(4):200-213. PubMed ID: 32214912
    [TBL] [Abstract][Full Text] [Related]  

  • 87. A practical approach to managing patients with HCV infection.
    Huang RH; Hu KQ
    Int J Med Sci; 2006; 3(2):63-8. PubMed ID: 16614745
    [TBL] [Abstract][Full Text] [Related]  

  • 88. The Hep-CORE policy score: A European hepatitis C national policy implementation ranking based on patient organization data.
    Palayew A; Stumo SR; Cooke GS; Hutchinson SJ; Jauffret-Roustide M; Maticic M; Harris M; Metwally AM; Razavi H; Lazarus JV;
    PLoS One; 2020; 15(7):e0235715. PubMed ID: 32722701
    [TBL] [Abstract][Full Text] [Related]  

  • 89. New direct-acting antivirals for hepatitis C treatment and neuropsychiatric symptoms in psychiatric risk groups.
    Miarons M; Sánchez-Ulayar A; Sempere G; Marín S; Castellví JM
    Eur J Hosp Pharm; 2019 May; 26(3):135-139. PubMed ID: 31428320
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Meningitis: a frequently fatal diagnosis in Africa.
    von Gottberg A; Meintjes G
    Lancet Infect Dis; 2019 Jul; 19(7):676-678. PubMed ID: 31250809
    [No Abstract]   [Full Text] [Related]  

  • 91. Deep sequencing and phylogenetic analysis of variants resistant to interferon-based protease inhibitor therapy in chronic hepatitis induced by genotype 1b hepatitis C virus.
    Sato M; Maekawa S; Komatsu N; Tatsumi A; Miura M; Muraoka M; Suzuki Y; Amemiya F; Takano S; Fukasawa M; Nakayama Y; Yamaguchi T; Uetake T; Inoue T; Sato T; Sakamoto M; Yamashita A; Moriishi K; Enomoto N
    J Virol; 2015 Jun; 89(11):6105-16. PubMed ID: 25810555
    [TBL] [Abstract][Full Text] [Related]  

  • 92. New direct-acting antivirals' combination for the treatment of chronic hepatitis C.
    Asselah T; Marcellin P
    Liver Int; 2011 Jan; 31 Suppl 1():68-77. PubMed ID: 21205141
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Molecular characterization of hepatitis C virus in liver disease patients in Botswana: a retrospective cross-sectional study.
    Bhebhe L; Anderson M; Souda S; Choga WT; Zumbika E; Shaver ZM; Mbangiwa T; Phinius BB; Banda CC; Melamu P; Musonda RM; Essex M; Blackard JT; Moyo S; Gaseitsiwe S
    BMC Infect Dis; 2019 Oct; 19(1):875. PubMed ID: 31640596
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group.
    Nousbaum JB; Pol S; Nalpas B; Landais P; Berthelot P; Bréchot C
    Ann Intern Med; 1995 Feb; 122(3):161-8. PubMed ID: 7810932
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Hepatitis C Virus: Viral Quasispecies and Genotypes.
    Tsukiyama-Kohara K; Kohara M
    Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29271914
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.
    Charlton M; Gane E; Manns MP; Brown RS; Curry MP; Kwo PY; Fontana RJ; Gilroy R; Teperman L; Muir AJ; McHutchison JG; Symonds WT; Brainard D; Kirby B; Dvory-Sobol H; Denning J; Arterburn S; Samuel D; Forns X; Terrault NA
    Gastroenterology; 2015 Jan; 148(1):108-17. PubMed ID: 25304641
    [TBL] [Abstract][Full Text] [Related]  

  • 97.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 98.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 99.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.